The FDA approval addresses acquired endocrine resistance by allowing eligible patients with HR-positive, HER2-negative advanced breast cancer to switch to camizestrant when an ESR1 mutation is detected in...
An updated systematic review of randomized, placebo-controlled trials found that long-term combined and estrogen-only hormone therapy may have different risk-benefit profiles for stroke, breast cancer,...
In their Practical Updates in Primary Care session, Jeanne M. Ferrante, MD, MPH, and Nell Maloney Patel, MD, FACS, FASCRS, discussed evidence-based cancer screening updates for primary care, with emphasis...
July 2026 included several FDA drug and biologic approvals across a range of therapeutic areas. This timeline highlights the key alerts our publication covered throughout the month, giving readers a quick,...
The FDA approved gedatolisib with fulvestrant, with or without palbociclib, for adults with HR-positive, HER2-negative locally advanced or metastatic breast cancer without a PIK3CA mutation detected after...
June 2026 included several FDA drug and biologic approvals across a range of therapeutic areas. This timeline highlights the key alerts our publication covered throughout the month, giving readers a quick,...
The FDA approved sacituzumab govitecan-hziy (Trodelvy) as monotherapy, and with pembrolizumab-based therapy, for select adults with previously untreated unresectable locally advanced or metastatic...
May 2026 included several FDA drug and biologic approvals across a range of therapeutic areas. This timeline highlights the key alerts our publication covered throughout the month, giving readers a quick,...
In a phase 3 randomized trial of women with stage I-III breast cancer, a low-glycemic Mediterranean diet, brisk walking, and vitamin D did not reduce recurrence overall but improved weight and metabolic...
